Go to The Journal of Clinical Investigation
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Transfers
  • Advertising
  • Job board
  • Contact
  • Current issue
  • Past issues
  • By specialty
    • COVID-19
    • Cardiology
    • Immunology
    • Metabolism
    • Nephrology
    • Oncology
    • Pulmonology
    • All ...
  • Videos
  • Collections
    • Resource and Technical Advances
    • Clinical Medicine
    • Reviews
    • Editorials
    • Perspectives
    • Top read articles
  • JCI This Month
    • Current issue
    • Past issues

  • Current issue
  • Past issues
  • Specialties
  • In-Press Preview
  • Editorials
  • Viewpoint
  • Top read articles
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Transfers
  • Advertising
  • Job board
  • Contact
Stat3 regulates desmoglein 3 transcription in epithelial keratinocytes
Xuming Mao, … , Eric M. Mukherjee, Aimee S. Payne
Xuming Mao, … , Eric M. Mukherjee, Aimee S. Payne
Published May 4, 2017
Citation Information: JCI Insight. 2017;2(9):e92253. https://doi.org/10.1172/jci.insight.92253.
View: Text | PDF
Research Article Dermatology

Stat3 regulates desmoglein 3 transcription in epithelial keratinocytes

  • Text
  • PDF
Abstract

Pemphigus vulgaris (PV) is an epithelial blistering disease caused by autoantibodies to the desmosomal cadherin desmoglein 3 (DSG3). Glucocorticoids improve disease within days by increasing DSG3 gene transcription, although the mechanism for this observation remains unknown. Here, we show that DSG3 transcription in keratinocytes is regulated by Stat3. Treatment of primary human keratinocytes (PHKs) with hydrocortisone or rapamycin, but not the p38 MAPK inhibitor SB202190, significantly increases DSG3 mRNA and protein expression and correspondingly reduces phospho-S727 Stat3. Stat3 inhibition or shRNA-knockdown also significantly increases DSG3 mRNA and protein levels. Hydrocortisone- or rapamycin-treated PHKs demonstrate increased number and length of desmosomes by electron microscopy and are resistant to PV IgG–induced loss of cell adhesion, whereas constitutive activation of Stat3 in PHKs abrogates DSG3 upregulation and inhibits hydrocortisone and rapamycin’s therapeutic effects. Topical hydrocortisone, rapamycin, or Stat3 inhibitor XVIII prevents autoantibody-induced blistering in the PV passive transfer mouse model, correlating with increased epidermal DSG3 expression and decreased phospho-S727 Stat3. Our data indicate that glucocorticoids and rapamycin upregulate DSG3 transcription through inhibition of Stat3. These studies explain how glucocorticoids rapidly improve pemphigus and may also offer novel insights into the physiologic and pathophysiologic regulation of desmosomal cadherin expression in normal epidermis and epithelial carcinomas.

Authors

Xuming Mao, Michael Jeffrey T. Cho, Christoph T. Ellebrecht, Eric M. Mukherjee, Aimee S. Payne

×

Figure 1

Glucocorticoids and rapamycin increase desmoglein 3 (DSG3) transcription and bolster desmosomal adhesion through increased desmosome length and number.

Options: View larger image (or click on image) Download as PowerPoint
Glucocorticoids and rapamycin increase desmoglein 3 (DSG3) transcription...
(A) qPCR indicates a significant increase in DSG3 transcription after treatment of primary human keratinocytes (PHKs) with hydrocortisone (Hydro) and rapamycin (Rapa) but not the p38 inhibitor SB202190. *P < 0.05 (one-way ANOVA). (B) Hydrocortisone and rapamycin cause a dose-dependent increase in DSG3 protein levels and a decrease in phospho-S727 Stat3 (pStat3), shown by immunoblot. Results are representative of 2–3 different experiments. Electron microscopic analysis of PHKs (C, scale bar: 500 nm) indicates increased desmosome length (D) and number (E) after treatment with hydrocortisone and rapamycin (*P < 0.05, Wilcoxon rank-sum and 2 tailed Student’s t test, respectively), corresponding to significantly decreased PHK cell sheet fragmentation by PV IgG (F and G, results are representative of 3 different experiments). *P < 0.05 (one-way ANOVA).

Copyright © 2023 American Society for Clinical Investigation
ISSN 2379-3708

Sign up for email alerts